Katrina Goddard, PhD, is a genetic epidemiologist who focuses on public health genomics and the translation of genetic testing into practice. She joined the Kaiser Permanente Center for Health Research in 2007.
Dr. Goddard has directed or collaborated on more than 20 federally funded research studies. She is the co-principal investigator of a study that is exploring the use of genome sequencing in the clinical context of preconception carrier screening. She also led a project implementing universal tumor screening for Lynch syndrome and a National Cancer Institute (NCI)-funded collaboration to evaluate evidence on breast cancer genomic applications. She was the co-PI of the NCI-funded Grand Opportunity award CERGEN, which evaluated the cost, diffusion, and outcomes of KRAS testing to direct treatment decisions across 11 health care systems. She was also the site principal investigator for the GeneScreen pilot program that explored targeted genomic screening for medically actionable conditions in the adult general population.
Dr. Goddard was the founding director for the NW Biobank. She co-chaired a committee to develop plans for integration and coordination of biobanking activities across seven Kaiser Permanente regions. This planning led to the launch of the Kaiser Permanente Research Bank in 2014.
Dr. Goddard has contributed to knowledge synthesis products that have far-reaching impact for numerous national organizations. She currently directs the Knowledge Synthesis Team (KST) and co-chairs the Actionability Work Group for the ClinGen Consortium. The KST provides systematic evidence summaries on the ClinGen website for the entire genomics community.
Prior to her appointment as a Senior Investigator, Dr. Goddard was on the faculty at Case Western Reserve University in the Division of Genetic & Molecular Epidemiology. She was involved in several large-scale gene discovery projects there and was associate director of the Human Genetic Analysis Resource. She received her PhD in biostatistics from the University of Washington and a BS in molecular biology from the University of Wisconsin-Madison.
- Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012 Dec 5;104(23):1785-95. PMCID: PMC3514165
- Feigelson HS, Zeng C, Pawloski PA, Onitilo AA, Richards CS, Johnson MA, Kauffman TL, Webster J, Nyirenda C, Alexander GL, Hwang C, Cross D, McCarty CA, Davis RL, Schwarzkopf D, Williams AE, Honda S, Daida Y, Kushi LH, Delate T, Goddard KA; CERGEN Study Team. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One 2014 May 1;9(5):e94977. PMCID: PMC4006772
- Cross D, Rahm AK, Kauffman T, Webster J, Le A, Fiegelson HS, Alexander G, Meier P, Onitilo A, Pawloski P, Williams A, Honda S, Daida Y, McCarty C, Goddard K. Underutilization of Lynch Syndrome screening in a multisite study of colorectal cancer patients. Genetics in Medicine 2013 Dec;15(12):933-40. PMCID: PMC3855589
- Goddard KAB, Whitlock EP, Berg JS, Williams MS, Webber EM, Webster JA, Lin JS, Schrader KA, Campos-Outcalt D, Offit K, Feigelson HS, Hollombe C. Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med 2013 Sep;15(9):721-8. PMCID: PMC3927794
- Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec. Report No.: 12-05164-EF-1.
- Lin JS, Webber EM, Beil TL, Goddard KA, Whitlock EP. Fecal DNA testing in screening for colorectal cancer in average-risk adults. Comparative Effectiveness Review No. 52. AHRQ Publication No. 12-EHC022-EF. Agency for Healthcare Research and Quality, Rockville, MD. February 2012.
- Webber EM, Kauffman TL, O’Connor E, Goddard KAB. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 2015 Mar 21;15:156. PMCID: PMC4376504
- Betsou F, Gunter E, Clements J, Desouza Y, Goddard KA, Guadagni F, Yan W, Skubitz A, Somiari S, Yeadon T, Chuaqui R. Identification of evidence-based biospecimen quality-control tools: A report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn 2013 Jan;15(1):3-16.
- Goddard KAB, Smith KS, Chen C, McMullen C, Johnson C. Biobank recruitment: Motivations for non-participation. Biopreservation and Biobanking 2009 June;7(2):119-121. PMCID: PMC3205734
- Goddard KAB, Ziegler A, Wellek S. Adapting the logical basis of tests for Hardy-Weinberg equilibrium to the real needs of association studies in human and medical genetics. Genet Epidemiol 2009 Nov;33(7):569-80.